Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 89,500 shares, a growth of 41.2% from the January 31st total of 63,400 shares. Currently, 17.1% of the company’s shares are short sold. Based on an average trading volume of 223,600 shares, the days-to-cover ratio is presently 0.4 days.

Revelation Biosciences Stock Performance

REVB stock traded up $0.10 during trading on Wednesday, hitting $3.55. 8,395 shares of the company traded hands, compared to its average volume of 102,733. The firm has a market capitalization of $950,060.00, a PE ratio of -0.01 and a beta of 0.17. Revelation Biosciences has a 1 year low of $3.19 and a 1 year high of $60.80. The company has a 50-day moving average of $5.55 and a 200-day moving average of $10.33.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.